Troponin I ELISA Kit

Catalog No. ABIN996909

Product Details Troponin I ELISA Kit

Target: Troponin I (TNNI)

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 0-75 ng/mL

Minimum Detection Limit: 0 ng/mL

Application: ELISA

Purpose: The cTnI Enzyme Immunoassay provides a rapid, sensitive, and reliable assay for the quantitative measurement of cardiac-specific troponin I.

Sample Type: Serum

Analytical Method: Quantitative

Specificity: 96 %

Sensitivity: 1 ng/mL

Characteristics: The antibodies developed for the test will determine a minimal concentration of 1.0 ng/ml, and there is no cross-reactivity with human cardiac troponin T or skeletal troponin T or I. Principle of the Assay The cTnI ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes four unique monoclonal antibodies directed against distinct antigenic determinants on the molecule. Three mouse monoclonal anti-troponin I antibodies are used for solid phase immobilization (on the microtiter wells). The fourth antibody is in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react simultaneously with the four antibodies, resulting in the troponin I molecules being sandwiched between the solid phase and enzyme-linked antibodies. After a 90-minute incubation at room temperature, the wells are washed with water to remove unbound-labeled antibodies. A solution of tetramethylbenzidine (TMB) Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of 1N hydrochloric acid (HCl) changing the color to yellow.

Application Details

Sample Volume: 100 μL

Assay Time: 1 - 2 h

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Expiry Date: 12-14 months

Target Details for Troponin I

Target: Troponin I (TNNI)

Alternative Name: Troponin I (TNNI Products)

Synonyms: CG7178 ELISA Kit, DROTROPONI ELISA Kit, DmTpnI ELISA Kit, Dmel\\CG7178 ELISA Kit, HDP ELISA Kit, HL-I ELISA Kit, HL08042 ELISA Kit, HLI ELISA Kit, Tn I ELISA Kit, TnI ELISA Kit, TpnI ELISA Kit, WupA ELISA Kit, hdp ELISA Kit, hdp2 ELISA Kit, wup-A ELISA Kit, tni ELISA Kit, wings up A ELISA Kit, troponin I ELISA Kit, putative troponin I ELISA Kit, wupA ELISA Kit, tni ELISA Kit, LOC5574015 ELISA Kit, Smp_059170.1 ELISA Kit

Background: Troponin is the inhibitory or contractile regulating protein complex of striated muscle. It is located periodically along the thin filament of the muscle and consists of three distinct proteins: troponin I, troponin C, and troponin T. Likewise, the troponin I subunit exists in three separate isoforms, two in fast-twitch and slow-twitch skeletal muscle fibers, and one in cardiac muscle. The cardiac isoform (cTnI) is about 40% dissimilar, has a molecular weight of 22,500 daltons, and has 31 additional amino acid residues that are not present on the skeletal isoforms. Antibodies made against this cardiac isoform are immunologically different from antibodies made against the other two skeletal isoforms and the unique isoform and tissue specificity of cardiac troponin I is the basis for its use as an aid in the diagnosis of acute myocardial infarction (AMI).

Cardiac troponin I (cTnI) has been useful in the differential diagnosis of patients presenting to Emergency Departments (ED) with chest pain. Myocardial infarction is diagnosed when blood levels of sensitive and specific biomarkers, such as cardiac troponin, the MB isoenzyme of creatine kinase (CK-MB), and myoglobin, are increased in a clinical setting of acute ischemia.
The most recently described and preferred biomarker for myocardial damage is cardiac troponin (I or T). The cardiac troponins exhibit myocardial tissue specificity and high sensitivity. Likewise, cardiac TnI and CK-MB have similar release patterns (4-6 hours after the onset of pain), but the level of cTnI remains elevated for a much longer period of time (6-10 days), thus providing for a longer window of detection of cardiac injury.
Normal levels of cTn I in the blood are very low. After the onset of an AMI, cTnI levels increase substantially and are measurable in serum within 4 to 6 hours, with peak concentrations reached in approximately 12 to 24 hours after infarction. The fact that cTnI remains elevated in serum for a much longer period of time, added to its enhanced diagnostic sensitivity and cardiac specificity, allows for the detection of AMI much earlier after the onset of ischemia (4 hours), 1,25 as well as the diagnosis of peri-operative infarction in situations where a high serum level of skeletal muscle proteins are expected.
Additionally, recent data have identified a measurable relationship between cardiac troponin levels and long-term outcome after an episode of chest discomfort. The studies suggest that the use of the cTnI demonstrates high predictive value in delineating the high risk group of unstable angina patients and that these tests may be particularly useful in evaluating patient condition prior to discharge from the ED.